Exciting developments in the biotech industry are paving the way for new treatments targeting high cholesterol. Recent studies presented at the American College of Cardiology Scientific Session have shown promising results for ANGPTL3-targeting drugs developed by Eli Lilly and Jiangsu Hengrui Pharmaceuticals. Eli Lilly’s solbinsiran, a small interfering RNA therapy, demonstrated significant reductions in apolipoprotein […]